Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorChen, Li T.
dc.contributor.authorMacarulla Mercadé, Teresa
dc.contributor.authorBlanc, Jean-Frédéric
dc.contributor.authorMirakhur, Beloo
dc.contributor.authorJong, Floris A. de
dc.contributor.authorBelanger, Bruce
dc.date.accessioned2020-02-20T14:04:08Z
dc.date.available2020-02-20T14:04:08Z
dc.date.issued2019-07-28
dc.identifier.citationChen LT, Macarulla T, Blanc JF, Mirakhur B, Jong FA, Belanger B, et al. Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer. Cancers. 2019 Jul 28;11(8):1068.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/4669
dc.descriptionNAPOLI-1; Liposomal irinotecan; Survival outcomes
dc.description.abstractNAPOLI-1 (NCT01494506) was a phase III study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. This post hoc analysis of NAPOLI-1 aimed to develop a predictive nomogram for overall survival (OS) at 6 and 12 months. Analyses were derived from all patients in NAPOLI-1 randomized to receive nal-IRI+5-FU/LV, nal-IRI monotherapy, or 5-FU/LV combination therapy. OS was associated with baseline factors using univariate and multivariable Cox analyses. A predictive nomogram was derived and validated using a concordance index and calibration plots. The univariate analyses identified 21 independent factors that contributed to OS, with eight factors significantly associated with OS. The Karnofsky Performance Score contributed the largest number of points (100), followed by presence of liver metastasis (98) and randomization to nal-IRI+5-FU/LV (96). The other baseline factors showing effects were albumin (g/dL), neutrophil/lymphocyte ratio, carbohydrate antigen 19-9 (U/mL), disease stage at diagnosis, and body mass index (kg/m2). The nomogram was used to predict the 6- and 12-month survival probability. The mean absolute errors between the observed and predicted probabilities for OS at 3, 6, and 9 months were 0.07, 0.08, and 0.07, respectively. This nomogram, based on NAPOLI-1, provides additional insight to aid decision-making for patients with mPDAC after previous gemcitabine-based therapy.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;11(8)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectNomografia (Matemàtica)
dc.subjectPàncrees - Càncer
dc.subjectMedicaments antineoplàstics
dc.subject.meshNomograms
dc.subject.meshNeoplasm Metastasis
dc.subject.mesh/Pancreas
dc.subject.meshAntineoplastic Agents
dc.titleNomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers11081068
dc.subject.decsnomogramas
dc.subject.decsmetástasis neoplásica
dc.subject.decs/Páncreas
dc.subject.decsantineoplásicos
dc.relation.publishversionhttps://www.mdpi.com/2072-6694/11/8/1068
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Chen LT ] National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. [Macarulla T] Hospital Universitari Vall d’Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain. [Blanc JF] Groupe Hospitalier Haut-Lévêque, CHU Bordeaux, Pessac, France. [Mirakhur B] Ipsen Biopharmaceuticals, Inc., Basking Ridge, USA. [Jong FA] Global Medical Affiars, Servier, Zürich, Switzerland. [Belanger B] Ipsen Biopharmaceuticals, Inc., Cambridge, USA
dc.identifier.pmid31357748
dc.identifier.wos000484438000028
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record